Amedisys, Inc. (NASDAQ:AMED) Shares Acquired by Highbridge Capital Management LLC

Highbridge Capital Management LLC increased its position in Amedisys, Inc. (NASDAQ:AMED - Free Report) by 34.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 323,200 shares of the health services provider's stock after purchasing an additional 83,200 shares during the quarter. Highbridge Capital Management LLC owned approximately 0.99% of Amedisys worth $29,670,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Vanguard Personalized Indexing Management LLC boosted its stake in shares of Amedisys by 12.9% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 5,421 shares of the health services provider's stock valued at $498,000 after purchasing an additional 619 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Amedisys by 4.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 514,166 shares of the health services provider's stock valued at $47,202,000 after acquiring an additional 19,660 shares in the last quarter. Alpine Associates Management Inc. increased its holdings in shares of Amedisys by 0.9% in the 2nd quarter. Alpine Associates Management Inc. now owns 1,280,897 shares of the health services provider's stock valued at $117,586,000 after acquiring an additional 11,000 shares during the period. Parallel Advisors LLC increased its holdings in shares of Amedisys by 28.9% in the 2nd quarter. Parallel Advisors LLC now owns 3,690 shares of the health services provider's stock valued at $339,000 after acquiring an additional 827 shares during the period. Finally, Eubel Brady & Suttman Asset Management Inc. boosted its stake in Amedisys by 66.4% in the second quarter. Eubel Brady & Suttman Asset Management Inc. now owns 8,439 shares of the health services provider's stock valued at $775,000 after acquiring an additional 3,368 shares in the last quarter. 94.36% of the stock is currently owned by hedge funds and other institutional investors.

Amedisys Stock Up 0.1 %

NASDAQ:AMED traded up $0.06 during midday trading on Thursday, hitting $97.21. 337,617 shares of the company were exchanged, compared to its average volume of 326,482. Amedisys, Inc. has a fifty-two week low of $89.55 and a fifty-two week high of $98.95. The company has a current ratio of 1.16, a quick ratio of 1.16 and a debt-to-equity ratio of 0.30. The company has a market capitalization of $3.18 billion, a PE ratio of -151.95, a price-to-earnings-growth ratio of 1.89 and a beta of 0.78. The company has a fifty day simple moving average of $97.73 and a 200 day simple moving average of $94.77.

Amedisys (NASDAQ:AMED - Get Free Report) last announced its quarterly earnings data on Wednesday, July 24th. The health services provider reported $1.32 EPS for the quarter, beating analysts' consensus estimates of $1.22 by $0.10. The firm had revenue of $591.19 million during the quarter, compared to the consensus estimate of $579.34 million. Amedisys had a net margin of 4.02% and a return on equity of 12.39%. As a group, equities analysts anticipate that Amedisys, Inc. will post 4.66 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. William Blair lowered Amedisys from an "outperform" rating to a "market perform" rating in a research note on Monday, July 1st. Cantor Fitzgerald reissued a "neutral" rating and issued a $101.00 price target on shares of Amedisys in a research note on Thursday, July 25th. Finally, Deutsche Bank Aktiengesellschaft lowered Amedisys from a "buy" rating to a "hold" rating and set a $101.00 price objective for the company. in a research note on Monday, July 29th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $100.67.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.